Last updated: October 26, 2026
Spravato, Johnson & Johnson’s intranasal esketamine product, has developed into a high-growth specialty psychiatry franchise. Global sales increased from approximately $170 million in 2020 to $689 million in 2023, driven by broader physician adoption, payer coverage, treatment-center expansion, and demand for alternatives to conventional antidepressants. The principal constraints are administration-site requirements, REMS compliance, reimbursement friction, controlled-substance handling, and the need for repeat dosing.
Spravato is a small molecule, so biosimilar competition does not apply. Future erosion will depend on generic esketamine timing, Orange Book-listed patents, patent litigation, device and formulation barriers, and whether competing treatments such as oral antidepressants, Auvelity, transcranial magnetic stimulation, electroconvulsive therapy, and off-label ketamine capture patients.
How large is the Spravato market?
Spravato addresses treatment-resistant depression, a segment of major depressive disorder in which patients fail to achieve adequate response after conventional antidepressant therapy. The commercial market is defined less by the total number of depression patients than by the subset with treatment resistance, specialist access, and insurance coverage.
Spravato’s eligible market has expanded through three commercial channels:
- Psychiatric practices and hospital outpatient departments that administer the product under observation.
- Specialty mental-health centers that build recurring treatment capacity.
- Health systems seeking alternatives to electroconvulsive therapy or long sequences of ineffective oral antidepressants.
The product is administered intranasally under direct observation. Patients are monitored for sedation, dissociation, blood-pressure increases, and other adverse effects. This model limits pharmacy-only dispensing but creates recurring revenue per treatment session.
What patient population does Spravato target?
The FDA initially approved Spravato in March 2019 for adults with treatment-resistant depression, in combination with an oral antidepressant. In July 2020, the FDA approved it for depressive symptoms in adults with major depressive disorder accompanied by acute suicidal ideation or behavior, also with an oral antidepressant. The prescribing information states that Spravato has not been shown to prevent suicide or reduce suicidal behavior, and that hospitalization may still be required for patients at imminent risk. (U.S. Food and Drug Administration, 2023)
The commercial opportunity is concentrated in patients who:
- Have failed multiple oral antidepressants.
- Can access a certified treatment site.
- Have insurance coverage for repeated administrations.
- Tolerate dissociation and monitoring requirements.
- Prefer a pharmacologic intervention over ECT or other procedures.
What are Spravato’s sales and financial trajectory?
Johnson & Johnson’s reported product sales show a steep post-launch ramp.
| Fiscal year |
Spravato sales |
Year-over-year change |
| 2019 |
Approximately $41 million |
Launch year |
| 2020 |
Approximately $170 million |
Approximately 315% |
| 2021 |
Approximately $303 million |
Approximately 78% |
| 2022 |
Approximately $550 million |
Approximately 82% |
| 2023 |
Approximately $689 million |
Approximately 25% |
Sources: Johnson & Johnson annual reports for fiscal years 2020 through 2023.
The trajectory has three phases. The first was launch formation in 2019 and 2020, when the product faced operational disruption from the COVID-19 pandemic and limited treatment-site capacity. The second was rapid expansion in 2021 and 2022 as clinics reopened and physicians gained experience with patient selection and monitoring. The third was continued growth in 2023 at a slower rate, reflecting a larger commercial base and ongoing reimbursement and capacity limits.
The 2023 revenue level represented about 1.3% of Johnson & Johnson’s Innovative Medicine sales, based on segment revenue of approximately $54.8 billion. Spravato is not financially material to the group as a whole, but it is strategically relevant as a growth product in neuroscience. (Johnson & Johnson, 2024)
What is driving Spravato revenue growth?
The main revenue drivers are:
- Increased recognition of treatment-resistant depression as a distinct treatment category.
- Greater use after failure of multiple oral antidepressants.
- More certified sites and trained clinicians.
- Better payer familiarity with prior-authorization criteria.
- Repeat dosing and maintenance treatment.
- Promotion of the product’s rapid antidepressant effect relative to conventional therapies.
- Use in patients for whom ECT, TMS, or hospitalization is unsuitable or undesirable.
Repeat treatment creates a different revenue profile from a conventional daily antidepressant. A patient who remains on maintenance therapy can generate recurring site-based revenue over an extended period. The same feature increases payer scrutiny because treatment costs accumulate across multiple administrations.
How does Spravato compare with competing depression treatments?
Spravato competes with both branded therapies and treatment modalities rather than with a single direct substitute.
| Treatment |
Administration |
Main commercial advantage |
Main limitation |
| Spravato |
Intranasal, observed in certified site |
Rapid onset and recurring maintenance use |
REMS, monitoring, dissociation, cost |
| Oral antidepressants |
Pharmacy-dispensed |
Low cost and broad access |
Delayed response and treatment failure |
| Auvelity |
Oral, at-home |
Non-REM sleep? Direct outpatient use and rapid-onset positioning |
Newer payer adoption and oral tolerability |
| TMS |
Clinic-based procedure |
Non-drug option without systemic medication exposure |
Multiple sessions and equipment investment |
| ECT |
Hospital or specialty facility |
Strong efficacy in severe depression |
Anesthesia, cognitive effects, infrastructure |
| Off-label ketamine |
Infusion or compounded routes |
Rapid effect and flexible clinical use |
Variable evidence, regulation, and reimbursement |
Auvelity, developed by Axsome Therapeutics, is an important branded competitor in treatment-resistant depression. It offers oral administration and avoids the Spravato REMS process, but it does not replicate Spravato’s intranasal esketamine mechanism or administration model.
Off-label ketamine is a commercial substitute in some clinics. Ketamine may be delivered intravenously, intramuscularly, orally, or through compounded formulations. Its lower-cost or flexible administration can pressure Spravato in cash-pay markets, while Spravato benefits from FDA approval, standardized dosing, and manufacturer-supported reimbursement infrastructure.
What is the FDA regulatory status of Spravato?
Spravato is approved under NDA 211243. Its FDA-approved uses are:
| FDA milestone |
Date |
Regulatory significance |
| Initial approval |
March 2019 |
Treatment-resistant depression in adults, with an oral antidepressant |
| Expanded indication |
July 2020 |
Depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior |
| REMS |
Required |
Administration and monitoring at certified sites |
The REMS requires that Spravato be administered in a certified health-care setting, that patients be monitored after dosing, and that the product not be dispensed for unsupervised home use. These requirements increase operating costs but also create a regulatory barrier to casual substitution with compounded or generic products. (U.S. Food and Drug Administration, 2023)
The label requires oral antidepressant therapy for the approved indications. That restriction shapes prescribing economics because Spravato is generally positioned as an add-on or escalation therapy rather than a replacement for all background pharmacotherapy.
What patents protect Spravato and when could generic entry occur?
Spravato is protected by a combination of composition, formulation, manufacturing, delivery, and method-of-use rights. The relevant protection is not limited to the esketamine molecule itself. Commercial barriers include:
- Intranasal delivery technology.
- Device and dose-delivery characteristics.
- Formulation stability and concentration.
- Manufacturing processes for pharmaceutical-grade esketamine.
- Treatment methods for resistant depression.
- Use in defined patient populations.
- Regulatory exclusivity and REMS-linked operational requirements.
The FDA Orange Book identifies patents associated with NDA 211243. Generic applicants would generally need to address listed patents through an ANDA certification, including a Paragraph IV certification if the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.
Is there biosimilar risk for Spravato?
No. Spravato is a chemically synthesized small molecule, not a biologic. The relevant future competitor would be a generic esketamine product filed through the ANDA pathway, not a biosimilar filed under the Biologics Price Competition and Innovation Act.
A generic entrant would still face practical barriers:
- Demonstrating bioequivalence for the intranasal product.
- Matching dose delivery and device performance.
- Addressing Orange Book-listed patents.
- Operating within FDA REMS requirements.
- Obtaining payer placement against an established branded product.
- Establishing treatment-site distribution and clinician support.
What Paragraph IV challenges and patent litigation affect Spravato?
Publicly reported Spravato financial disclosures through Johnson & Johnson’s 2023 annual filing do not identify a material Paragraph IV litigation event affecting the product’s commercial outlook. The absence of a disclosed event does not establish that no patent challenge has been filed.
A meaningful generic challenge would probably focus on formulation, delivery, method-of-use, or patent-validity issues rather than the basic clinical concept of using esketamine. The commercial effect would depend on whether a settlement permits an authorized generic or delayed launch.
How strong is the Spravato patent estate?
The estate has moderate-to-strong commercial value because it combines regulatory protection with a specialized delivery system and controlled administration. Its strength is greater than the protection available for a simple oral small molecule with an expired composition patent.
The main weaknesses are structural:
- Esketamine is a known active pharmaceutical ingredient.
- The product’s mechanism and therapeutic category are well established.
- Generic developers can target specific formulation or device claims.
- Some method-of-use claims may face validity or infringement disputes.
- Off-label ketamine provides a non-generic substitute.
The strongest commercial defense is the integrated system of product, device, treatment protocol, certified sites, and payer infrastructure. Patent protection alone is unlikely to explain the entire duration of Spravato’s franchise.
What is the Orange Book status of Spravato?
Spravato is listed in the FDA Orange Book under NDA 211243. Orange Book protection can cover patents associated with the approved nasal spray product and its labeled uses. The economic relevance of each listing depends on:
- Patent expiration date.
- Whether the claim covers the commercial product.
- Whether the claim is vulnerable to invalidity challenges.
- Whether an ANDA applicant must certify against it.
- Whether the FDA grants pediatric exclusivity or other statutory extensions.
Orange Book status should be evaluated at the individual patent and claim level. A single expiration date for the brand is not sufficient because formulation, method, and device patents may expire at different times.
How do reimbursement and treatment-site economics affect demand?
Spravato is more expensive to administer than an ordinary prescription antidepressant because each dose requires a certified site, staff time, observation, documentation, and controlled-substance procedures.
The treatment-site economics depend on:
- Acquisition cost and reimbursement spread.
- Facility and nursing costs.
- Patient volume per clinic.
- Payer authorization speed.
- Cancellation rates.
- Monitoring duration.
- Maintenance-treatment frequency.
- Whether the site can operate efficiently at scale.
Commercial adoption is strongest where psychiatric practices can organize recurring appointment capacity. Smaller practices may avoid the product because of compliance burden, low patient volume, or uncertain reimbursement. Hospital outpatient departments and specialized behavioral-health networks have an operating advantage.
What licensing deals and commercial partnerships affect Spravato?
Spravato is primarily a Johnson & Johnson internal commercial franchise. Its strategic value comes from Janssen’s development, manufacturing, regulatory, and commercial infrastructure rather than from a publicly prominent external licensing model.
The company has used broad provider education, patient-support programs, treatment-site certification, and payer engagement to expand access. The market is therefore shaped by distribution and service infrastructure as much as by conventional pharmaceutical promotion.
No major third-party licensing transaction is required to explain Spravato’s current market position. The central commercial relationship is between Johnson & Johnson, certified providers, specialty pharmacies or controlled distribution channels, and health insurers.
What generic launch scenarios exist for Spravato?
Three scenarios are commercially plausible.
Delayed generic entry
A generic applicant challenges patents but launches only after settlement or litigation resolution. Johnson & Johnson preserves substantial branded revenue through maintenance patients and provider loyalty.
Single generic entrant
One approved generic enters with limited site coverage and lower payer reimbursement. Price erosion is meaningful but slower than for a pharmacy-dispensed tablet because administration infrastructure remains necessary.
Multiple generic entrants
Several manufacturers enter after core patent barriers fall. Payers impose stronger substitution incentives, branded pricing declines, and Johnson & Johnson may defend share through contracting, patient support, or an authorized generic strategy.
The slowest erosion case is likely if device, formulation, and method patents remain enforceable after basic molecule protection expires. The fastest erosion case would involve multiple ANDA approvals, weak brand differentiation, and payer-mandated substitution.
What is the revenue exposure if Spravato loses exclusivity?
Spravato’s direct group-level exposure is limited because the product contributes a small percentage of Johnson & Johnson’s total pharmaceutical revenue. Its franchise-level exposure is higher because it is one of the company’s most visible growth products in neuroscience.
Revenue risk would be concentrated in:
- U.S. sales, where the product launched first and reimbursement is commercially important.
- High-volume treatment centers.
- Maintenance patients with established response.
- Payers that move quickly to generic substitution.
- Markets where the product has limited differentiation from compounded ketamine.
International sales are affected by country-specific reimbursement, regulatory approval, and controlled-substance rules. Generic entry timing will therefore differ by jurisdiction.
Key Takeaways
- Spravato sales increased from approximately $170 million in 2020 to $689 million in 2023.
- Growth is driven by treatment-resistant depression, repeat dosing, site expansion, and broader payer acceptance.
- The product’s principal competitive advantage is rapid-onset treatment delivered through an FDA-approved, standardized program.
- REMS obligations, monitoring, and administration-site costs limit adoption but also create barriers to casual substitution.
- Spravato faces competition from oral antidepressants, Auvelity, TMS, ECT, and off-label ketamine.
- Biosimilar competition does not apply. Generic ANDA competition is the relevant risk.
- Patent value extends beyond the esketamine molecule to formulation, delivery, device, manufacturing, and method-of-use claims.
- Johnson & Johnson’s group-level revenue exposure is modest, but Spravato is strategically important within neuroscience.
- The likely long-term erosion profile depends on Orange Book patents, Paragraph IV activity, generic device equivalence, payer policy, and the strength of the treatment-site network.
FAQs
Is Spravato profitable for Johnson & Johnson?
Johnson & Johnson does not publicly disclose product-level profit margins. Spravato’s recurring treatment model supports attractive gross-margin potential, but site certification, monitoring, patient support, and reimbursement costs reduce contribution relative to a simple oral product.
Can patients take Spravato at home?
No. FDA-approved Spravato must be administered in a certified health-care setting under observation. Patients cannot take the product home for unsupervised use under the approved REMS framework.
Is Spravato covered by Medicare?
Coverage depends on the indication, site of care, Medicare benefit pathway, local contractor policy, and prior-authorization requirements. Coverage is generally more complex than for standard prescription antidepressants because administration and monitoring are integral to treatment.
Is generic esketamine likely to be cheaper than Spravato?
A generic could reduce acquisition cost, but total treatment cost would still include certified-site administration, monitoring, and professional services. Savings may therefore be smaller than the price reduction for a conventional generic tablet.
Does Spravato replace electroconvulsive therapy?
No. Spravato is an alternative treatment for some patients with severe or treatment-resistant depression. ECT remains an important option, particularly when rapid and robust clinical response is required or when other treatments fail.
References
Johnson & Johnson. (2021). 2020 annual report. Johnson & Johnson.
Johnson & Johnson. (2022). 2021 annual report. Johnson & Johnson.
Johnson & Johnson. (2023). 2022 annual report. Johnson & Johnson.
Johnson & Johnson. (2024). 2023 annual report. Johnson & Johnson.
U.S. Food and Drug Administration. (2023). Spravato (esketamine) nasal spray prescribing information. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
